G. D. Demetri

3.8k total citations · 2 hit papers
75 papers, 3.1k citations indexed

About

G. D. Demetri is a scholar working on Pulmonary and Respiratory Medicine, Gastroenterology and Hematology. According to data from OpenAlex, G. D. Demetri has authored 75 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Pulmonary and Respiratory Medicine, 33 papers in Gastroenterology and 20 papers in Hematology. Recurrent topics in G. D. Demetri's work include Gastrointestinal Tumor Research and Treatment (33 papers), Sarcoma Diagnosis and Treatment (27 papers) and Gastric Cancer Management and Outcomes (17 papers). G. D. Demetri is often cited by papers focused on Gastrointestinal Tumor Research and Treatment (33 papers), Sarcoma Diagnosis and Treatment (27 papers) and Gastric Cancer Management and Outcomes (17 papers). G. D. Demetri collaborates with scholars based in United States, France and Switzerland. G. D. Demetri's co-authors include JD Griffin, Margaret von Mehren, Michael C. Heinrich, T J Ernst, JD Griffin, Alec Ritchie, James D. Griffin, Charles D. Blanke, Charles M. Baum and Paolo G. Casali and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

G. D. Demetri

75 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Granulocyte colony-stimulating factor and its receptor

1991 833 citations G. D. Demetri, JD Griffin Blood profile →
Granulocyte colony-stimulating factor and its receptor

1991 697 citations G. D. Demetri, JD Griffin Blood profile →

Peers

Countries citing papers authored by G. D. Demetri

Since Specialization

Citations

This map shows the geographic impact of G. D. Demetri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. D. Demetri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. D. Demetri more than expected).

Fields of papers citing papers by G. D. Demetri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. D. Demetri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. D. Demetri. The network helps show where G. D. Demetri may publish in the future.

Co-authorship network of co-authors of G. D. Demetri

This figure shows the co-authorship network connecting the top 25 collaborators of G. D. Demetri. A scholar is included among the top collaborators of G. D. Demetri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. D. Demetri. G. D. Demetri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and safety of patients treated long-term with trabectedin (t) on the expanded access program: A retrospective analysis 2017 ·Annals of Oncology ·(unknown), Scott M. Schuetze, (unknown), Robert G. Maki, Robin L. Jones, Chu Ri Shin, Roland E. Knoblauch, (unknown), (unknown), G. D. Demetri, Priscilla Merriam	3
2	High rates of histopathologic discordance in sarcoma with implications for clinical care. 2011 ·Journal of Clinical Oncology ·Chandrajit P. Raut, S. George, Jason L. Hornick, James E. Butrynski, (unknown), John E. Ready, Alessandra F. Nascimento, (unknown), G. D. Demetri, E Baldini	11
3	Succinate dehydrogenase in KIT/PDGFRA wild-type gastrointestinal stromal tumors. 2010 ·Journal of Clinical Oncology ·Katherine A. Janeway, Soo‐Chan Kim, Maya Lodish, Vânia Nosé, Patricia L. M. Dahia, Pierre Rustin, G. D. Demetri, J. Fletcher, Lee J. Helman, Constantine A. Stratakis	3
4	Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001. 2010 ·Journal of Clinical Oncology ·Christopher L. Corless, Karla V. Ballman, C Antonescu, Charles D. Blanke, Martin E. Blackstein, G. D. Demetri, Margaret von Mehren, Robert G. Maki, Peter W. T. Pisters, Ronald P. DeMatteo	49
5	Measurement of interstitial fluid pressure (IFP) and circulating biomarkers in soft tissue sarcoma (STS): An exploratory phase II clinical and correlative study of sorafenib (SOR) in patients with refractory STS (NCI Protocol 6948). 2010 ·Journal of Clinical Oncology ·Chandrajit P. Raut, (unknown), R. Quek, Yves Boucher, (unknown), Johanna Lahdenranta, Marek Ancukiewicz, J. P. Eder, Rajan Jain, G. D. Demetri	3
6	Final reporting of a phase I clinical trial of the oral PPAR-gamma agonist, CS-7017, in patients with advanced malignancies. 2010 ·Journal of Clinical Oncology ·Michael J. Pishvaian, Ion Cotarla, Amy J. Wagner, John F. Deeken, Aiwu Ruth He, Jimmy J. Hwang, G. D. Demetri, (unknown), Catherine Copigneaux, John L. Marshall	5
7	Combination mTOR+IGF-IR inhibition: Phase I trial of everolimus and CP-751871 in patients (pts) with advanced sarcomas and other solid tumors. 2010 ·Journal of Clinical Oncology ·R. Quek, (unknown), Geoffrey I. Shapiro, James E. Butrynski, (unknown), (unknown), (unknown), Amy J. Wagner, G. D. Demetri, Sangeeth M. George	8
8	Soft tissue sarcoma (STS): Challenges in identification, treatment patterns, and costs of disease management in the U.S. 2008 ·Journal of Clinical Oncology ·James E. Butrynski, (unknown), A. Fournier, Érick Moyneur, (unknown), Maureen P. Neary, G. D. Demetri	1
9	Mechanisms of sunitinib malate (SU) resistance in gastrointestinal stromal tumors (GISTs) 2007 ·Journal of Clinical Oncology ·Michael C. Heinrich, Christopher L. Corless, Bernadette Liegl, Christopher D.�M. Fletcher, Chandrajit P. Raut, (unknown), Monica M. Bertagnolli, Amy Harlow, G. D. Demetri, Jonathan A. Fletcher	14
10	A randomized phase 2 study of the thrombospondin-mimetic peptide ABT-510 in patients with advanced soft tissue sarcoma (STS) 2005 ·Journal of Clinical Oncology ·Laurence H. Baker, G. D. Demetri, David S. Mendelson, Eric K. Rowinsky, Evelyn McKeegan, Raymond A. Knight, Dawn M. Carlson, Michael Lobell	14
11	A phase I/II trial of the oral mTOR-inhibitor everolimus (E) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM: Study update 2005 ·Journal of Clinical Oncology ·A. van Oosterom, Peter Reichardt, Jean‐Yves Blay, Herlinde Dumez, Jonathan A. Fletcher, Maria Dêbiec‐Rychter, N. Shand, (unknown), (unknown), G. D. Demetri	37
12	Levels of circulating endothelial cells (CECs) and monocytes as pharmacodynamic markers of SU11248 activity in patients (pts) with metastatic imatinib-resistant GIST 2005 ·Journal of Clinical Oncology ·(unknown), Judith Manola, (unknown), Jeffrey A. Morgan, Carlo L. Bello, (unknown), David R. Shalinsky, Charles M. Baum, G. D. Demetri, John V. Heymach	11
13	Dose effect of imatinib (IM) in patients (pts) with metastatic GIST - Phase III Sarcoma Group Study S0033 2004 ·Journal of Clinical Oncology ·Cathryn Rankin, Margaret von Mehren, Charles D. Blanke, R. S. Benjamin, Christopher D.�M. Fletcher, (unknown), John Crowley, Ernest C. Borden, G. D. Demetri	89
14	Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning 2004 ·Journal of Clinical Oncology ·Annick D. Van den Abbeele, Ramsey D. Badawi, Judith Manola, Jeffrey A. Morgan, Jayesh Desai, (unknown), (unknown), Charles M. Baum, G. D. Demetri	12
15	Safety and efficacy of percutaneous radio-frequency ablation (RFA) in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) with clonal evolution of lesions refractory to imatinib mesylate (IM) 2004 ·Journal of Clinical Oncology ·Palma Dileo, (unknown), Eric vanSonnenberg, (unknown), Jayesh Desai, Jeffrey A. Morgan, Kemal Tuncali, A. Van Den Abbeele, Stuart G. Silverman, G. D. Demetri	17
16	Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients. 1997 ·Journal of Clinical Oncology ·Charles L. Shapiro, Lois Ayash, Iain J. Webb, Rebecca Gelman, (unknown), (unknown), G. D. Demetri, P. Clark, AD Elias, David B. Duggan, Daniel Hayes, David D. Hurd, I. Craig Henderson	24
17	Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial. 1995 ·Journal of Clinical Oncology ·Dean F. Bajorin, C R Nichols, Hans‐Joachim Schmoll, Philip W. Kantoff, Carsten Bokemeyer, G. D. Demetri, (unknown), George J. Bosl	20
18	Effect of recombinant human interleukin‐3 on haematological recovery from chemotherapy‐induced myelosuppression 1994 ·British Journal of Haematology ·I Tepler, Anthony Elias, Leslie A. Kalish, Lawrence N. Shulman, Gary M. Strauss, Arthur T. Skarin, Thomas J. Lynch, Daniel Levitt, Debra Resta, G. D. Demetri, (unknown), Lowell E. Schnipper	14
19	Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy. 1993 ·Journal of Clinical Oncology ·I Tepler, S A Cannistra, Emil Frei, R Gonin, Kenneth C. Anderson, G. D. Demetri, Jonathan M. Niloff, H. M. Goodman, Howard G. Muntz, Michael G. Muto	67
20	Granulocyte colony-stimulating factor and its receptor breakdown → 1991 ·Blood ·G. D. Demetri, JD Griffin	833

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact